Literature DB >> 6986119

Syphilis serology today.

Y M Felman, J A Nikitas.   

Abstract

Serologic testing is an important adjunct in the diagnosis and management of syphilis. In this review, the various currently used serologic tests, both non-treponemal and treponemal, are considered. Special emphasis is placed on their relative advantages, applications, and limitations. Conditions under which these tests may be falsely positive are discussed. Additional diagnostic tools cited are the dark-field examination, for use in early-lesion syphilis, and cytological and immunochemical techniques for determining potentially active neurosyphilis. The analysis of every serologic report, and its correlation to the historical, epidemiological, and clinical findings, is highlighted.

Mesh:

Substances:

Year:  1980        PMID: 6986119

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  7 in total

Review 1.  Generalized lymphadenopathy.

Authors:  H Libman
Journal:  J Gen Intern Med       Date:  1987 Jan-Feb       Impact factor: 5.128

2.  Syphilis evaluation and therapy: a study of current practices in a university hospital.

Authors:  C Whiteside; F T Fitzgerald
Journal:  J Gen Intern Med       Date:  1988 Nov-Dec       Impact factor: 5.128

3.  Evaluation of an enzyme-linked immunosorbent assay for treponemal antibody.

Authors:  R W Stevens; M E Schmitt
Journal:  J Clin Microbiol       Date:  1985-03       Impact factor: 5.948

4.  Whole-blood hemagglutination inhibition test for venereal disease research laboratory (VDRL) antibodies.

Authors:  M P Meyer; R E Baughn
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

5.  Syphilitic myelopathy.

Authors:  M H Silber
Journal:  Genitourin Med       Date:  1989-10

6.  Biological false positive serological tests for syphilis in the Jamaican population.

Authors:  M F Smikle; O B James; P Prabhakar
Journal:  Genitourin Med       Date:  1990-04

Review 7.  Tubo-ovarian abscess: pathogenesis and management.

Authors:  N G Osborne
Journal:  J Natl Med Assoc       Date:  1986-10       Impact factor: 1.798

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.